Skip to main content
SpringerLink
Log in

p53 and Neu (c-erbB-2) Overexpression in Relation to Risk Factors for Breast Cancer

  • Conference paper
Hormonal Carcinogenesis II

  • 63 Accesses

Summary

Different types of breast cancer, with and without protein overexpression of neu (c-erbB-2) or p53, were studied to determine whether there was an association with known risk factors for breast cancer. Neu and p53 protein expressions were evaluated by immunohistochemistry in primary breast tumor samples from a series of patients aged 20–54 years, who participated in a case-control study. Neu overexpression was shown in 117 out of 597 tumors (19.6%) and p53 overexpression in 142 out of 528 tumors (26.9%). Diagnosis at a young age (≤35 years) was found to be associated with p53 and neu overexpression. Age at first full-term pregnancy (≥29 years) was more strongly related to neu[+] than to neu[−] tumors. Other risk factors were not significantly associated for breast tumors categorized according to neu or p53 protein expression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kelsey JL. (1993) Breast cancer epidemiology: Summary and future directions. Epidemiol Rev 15:256–63.

    PubMed  CAS  Google Scholar 

  2. Van de Vijver MJ (1993) Molecular genetic changes in human breast cancer. Adv Cancer Res 61:25–56.

    Article  PubMed  Google Scholar 

  3. Van de Vijver, et al. (1988) Neu-protein overexpression in breast cancer. N Engl J Med 319:1239–45.

    Article  PubMed  Google Scholar 

  4. Cattoretti G, et al. (1993) Antigen unmasking on formalin-fixed paraffin embedded tissue sections. J Path 171:83–98.

    Article  PubMed  CAS  Google Scholar 

  5. Fisher CJ, et al. (1994) Problems with p53 immunohistochemical staining. Brit J Cancer 69:26–31.

    Article  PubMed  CAS  Google Scholar 

  6. Hall PA, Lane DP (1994) p53 in tumour pathology. J Path 172:1–4.

    Article  PubMed  CAS  Google Scholar 

  7. Pietenpol JA, Vogelstein B (1993) No room at the p53 inn. Nature 365:17–8.

    Article  PubMed  CAS  Google Scholar 

  8. Jacquemier J, et al. (1994) P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies. Brit J Cancer 69:846–52

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Karin van der Kooy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matti A. Rookus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans L. Peterse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Flora E. van Leeuwen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Etiology and Prevention of Hormonal Cancers, Hormonal Carcinogenesis Laboratory, University of Kansas Cancer Center, Kansas City, Kansas, USA

    J. Jonathan Li Ph.D. (Professor of Pharmacology, Toxicology, and Therapeutics, Director) (Professor of Pharmacology, Toxicology, and Therapeutics, Director)

  2. Hormonal Carcinogenesis Laboratory, University of Kansas Cancer Center, Kansas City, Kansas, USA

    Sara Antonia Li Ph.D. (Associate Professor of Pharmacology, Toxicology, and Therapeutics) (Associate Professor of Pharmacology, Toxicology, and Therapeutics)

  3. Department of Medical Nutrition, Center for Biotechnology, NOVUM, Huddinge University Hospital, Huddinge, Sweden

    Jan-Åke Gustafsson M.D., Ph.D. (Professor and Chairman, Director) (Professor and Chairman, Director)

  4. Department of Molecular and Cell Biology, Cancer Research Center, University of California, Berkeley, California, USA

    Satyabrata Nandi Ph.D. (Professor of Cell and Development Biology) (Professor of Cell and Development Biology)

  5. Division of Cancer Etiology, Chemical and Physical Carcinogenesis Program, National Cancer Institute, Rockville, Maryland, USA

    Lea I. Sekely Ph.D. (Program Director) (Program Director)

  6. University of Kansas Medical Center, Kansas City, Kansas, USA

    J. Jonathan Li Ph.D. (Professor of Pharmacology, Toxicology, and Therapeutics, Director) & Sara Antonia Li Ph.D. (Associate Professor of Pharmacology, Toxicology, and Therapeutics) (Professor of Pharmacology, Toxicology, and Therapeutics, Director) &  (Associate Professor of Pharmacology, Toxicology, and Therapeutics)

  7. National Institutes of Health, Rockville, Maryland, USA

    Lea I. Sekely Ph.D. (Program Director) (Program Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag New York, Inc.

About this paper

Cite this paper

van der Kooy, K., Rookus, M.A., Peterse, H.L., van Leeuwen, F.E. (1996). p53 and Neu (c-erbB-2) Overexpression in Relation to Risk Factors for Breast Cancer. In: Li, J.J., Li, S.A., Gustafsson, JÅ., Nandi, S., Sekely, L.I. (eds) Hormonal Carcinogenesis II. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2332-0_48

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2332-0_48

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7506-0

  • Online ISBN: 978-1-4612-2332-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation